DAPA-HF One Year on: What Have You Missed?

Published: 31 July 2020

  • Views:

    Views Icon 177
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.

Agenda

  • Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
  • Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
  • DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
  • Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
  • Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)

More from this programme

Part 1

Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF

Part 2

Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF

Part 3

DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF

Part 4

Impact of Dapagliflozin Treatment on KCCQ

Part 5

Dapagliflozin and Diuretic Use in Patients With HFrEF

Faculty Biographies

Piotr Ponikowski

Piotr Ponikowski

Head of the Department of Heart Diseases

Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical rehabilitation in patients with chronic HF, assessment of metabolic derangements in HF (with special interest in iron deficiency), evaluation of reflex control in the cardiorespiratory system in order to optimise assessment and management of patients with HF. He has been involved in numerous clinical trials as main investigator, member of international steering committees, endpoint committees and advisory boards.

View full profile